Patents by Inventor Shaker A. Mousa

Shaker A. Mousa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9770419
    Abstract: The present invention provides a composition, a dairy product, and a method for treating a disorder in a subject. The composition includes (i) polymeric nanoparticles and (ii) camel derived glycosaminoglycans (GAG)s ionic complex encapsulated into the nanoparticles, at least one active ingredient encapsulated into the nanoparticles, or combinations thereof. The nanoparticles are lactoferrin nanoparticles including camel derived lactoferrin, casein nanoparticles including camel derived casein, or combinations thereof. The dairy product includes ice cream or frozen yogurt, wherein the ice cream or frozen yogurt includes the composition and is derived from camel milk or other species of milk. The method for treating a disorder in a subject includes administering a therapeutic dose of the composition to the subject.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: September 26, 2017
    Inventors: Shaker A. Mousa, Abdulqader Al Haider, Abdelgalil Abdelgader, Abdullah M. Aldahmash, Abdulkareem Almomen
  • Patent number: 9750709
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: September 5, 2017
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
  • Patent number: 9707318
    Abstract: A bone patch and method for treating a bone condition of an animal. The bone patch includes a composition of ingredients. The composition of ingredients include: stem cells; signaling molecules for osteoblast/endothelial differentiation; and scaffold material. The method for treating a bone condition includes: applying the bone patch to the animal for bone regeneration, treatment of a fractured bone, and/or treatment of a bone disorder.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: July 18, 2017
    Inventors: Shaker A. Mousa, Mohammed H. Qari, Mohammed S. Ardawi
  • Patent number: 9700042
    Abstract: The composition of the Nano carrier or Nano polymers composed of Hyaluronic Acid (15-25%) and fatty acids (50-70%) cross linked with ultra-Low molecular weight chitosan (15-25%) encapsulating isolated compounds from musk and their combinations for cosmetic use as anti-aging, anti-microbial, and fragrance. Additionally, these nano-encapsulated Musk bioactive compounds (MBC) at 0.1-10% (w/w MBC/Nano polymers) could be used in textile manufacturing (carpet/rugs and clothes) to provide anti-microbial and fragrance properties. Furthermore, Musk derived products are chemically conjugated to HA polymer, FA polymer, CH polymer, HA-CH co-polymer, FA-CH co-polymer or HA-CH-FA co-polymer to be incorporated into the fabric of the textile products (carpet/rugs or clothes).
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: July 11, 2017
    Inventors: Shaker A. Mousa, Amna Saddiq
  • Publication number: 20170189573
    Abstract: Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch.
    Type: Application
    Filed: January 12, 2017
    Publication date: July 6, 2017
    Inventors: Leo RUBIN, Shaker MOUSA
  • Patent number: 9682085
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: June 20, 2017
    Assignee: Shifa Biomedical Corporation
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil Elshourbagy, Harold Meyers, Shaker A. Mousa
  • Patent number: 9655862
    Abstract: An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA), chitosan, chitosan-alginate, and NIPAAM-APMAH-AA, wherein NIPAAM is N-isopropyl acrylamide, APMAH is N-3-aminopropylmethacrylamide hydrochloride, and AA is acrylic acid. A method for treating an eye disease of a subject includes: administering to an eye of the subject a therapeutically effective amount of the ophthalmic formulation for treating the eye disease. The eye disease involves an ocular angiogenesis-mediated disorder.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: May 23, 2017
    Inventor: Shaker A. Mousa
  • Publication number: 20170080058
    Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 23, 2017
    Inventors: Shaker A. Mousa, Paul J. Davis
  • Patent number: 9597351
    Abstract: This disclosure concerns novel formulation and Nanoformulations as defined in the specification and compositions comprising combination of HCV protease and polymerase inhibitors, with or without interferon, along with anti-fibrotic/anti-hemolytic agents' combination of naturally driven Polyphenol/Thiols, and Non-anticoagulant GAGs. These compounds are effective antiviral agents, especially in inhibiting the function of the various genotypes of Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising nano-targeted delivery of novel nanoformulation containing combined composition for HCV and/or hepatic targeted delivery for improved efficacy and safety.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: March 21, 2017
    Inventor: Shaker A. Mousa
  • Publication number: 20170071873
    Abstract: A nano-composition and a method of using the composition. The composition includes nanoparticles. Each nanoparticle includes a shell encapsulating lycopene. The shell includes oligomerized (?)-epigallocatechin-3-O-gallate (OEGCG) electrostatically bonded to chitosan. The method of using the composition includes administering the nano-composition to a human being.
    Type: Application
    Filed: September 9, 2016
    Publication date: March 16, 2017
    Inventors: Shaker A. Mousa, Mohammed H. Qari, Mohammed-Salleh M. Ardawi
  • Patent number: 9580395
    Abstract: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and ?v?3 integrin antagonist in the same molecule.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: February 28, 2017
    Assignee: VASCULAR VISION PHARMACEUTICAL COMPANY
    Inventor: Shaker A. Mousa
  • Patent number: 9579300
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: February 28, 2017
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
  • Publication number: 20170049710
    Abstract: Nanoparticles comprising VIP and their use in treating, e.g., pulmonary hypertension. Such nanoparticles provide improved delivery of VIP and allow for acute treatment and optionally for sustained release of VIP in a patient.
    Type: Application
    Filed: June 15, 2016
    Publication date: February 23, 2017
    Applicant: AVANT GARDE THERAPEUTICS AND TECHNOLOGIES, LLC
    Inventors: Leo RUBIN, Shaker MOUSA
  • Patent number: 9572831
    Abstract: A nanoformulation that includes nanoparticles. Each nanoparticle includes a shell in which a glycosaminoglycan (GAG is encapsulated. The GAG is ionically or covalently bonded to the shell. The GAG is selected from the group consisting of sulfated non-anticoagulant heparin (SNACH), super-sulfated non-anticoagulant heparin (S-SNACH), and a combination thereof. The shell includes Poly (lactic-co-glycolic acid) (PLGA), Polyethylene Glycol (PEG)-PLGA, maleimide-PEG-PLGA, chitosan, chitosan-PLGA, methoxy-polyethyleneglycol-poly (lactide-co-glycolide) (MPEG-PLGA)-(maleimide-PEG-PLGA), PLGA-Polycaprolate, or calcium alginate. A method of using the nanoformulation to treat a cancer in a subject includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the cancer.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: February 21, 2017
    Inventor: Shaker A. Mousa
  • Publication number: 20160346308
    Abstract: A composition and associated method for treating a hepatitis C virus (HCV) infection in a subject who is human being. The composition includes: an anti-viral agent and/or a protease inhibitor; a polymerase inhibitor; one or more viral entry inhibitors; and one or more anti-fibrotic agents and/or anti-hemolytic agents including one or more Polyphenols and/or one or more Thiols. The composition may also include one or more sulfated oligosaccharide or non-anticoagulant glycosaminoglycans (GAGs). The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventor: Shaker A. Mousa
  • Publication number: 20160338971
    Abstract: A nano-composition that includes nanoparticles, a method of forming the nano-composition, and a method of using the composition. The nanoparticles include a nano-shell and one or more compounds co-encapsulated within the nano-shell. The nano-shell of each nanoparticle includes one or more chitosan polymers and one or more polymers subject to each chitosan polymer being covalently bonded to the one or more polymer. Each chitosan polymer in the nano-shell of each nanoparticle includes chitosan, tri-methylated chitosan, or a combination thereof. The one or more polymers in the nano-shell of each nanoparticle include poly (lactide-co-glycolide) (PLGA), one or more fatty acids, or combinations thereof subject to each fatty acid including oligomer epigallocatechin-3-gallate (OEGCG), hyaluronic acid, oleic acids, myristic acid, caprylic acid, or combinations thereof.
    Type: Application
    Filed: February 1, 2016
    Publication date: November 24, 2016
    Inventors: Shaker A. Mousa, Soad K. Jaouni
  • Patent number: 9498536
    Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: November 22, 2016
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Paul J. Davis
  • Patent number: 9480703
    Abstract: A composition that includes a nanoparticle. The nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH). The shell includes poly L-arginine. The SNACH is ionically or covalently bonded to the poly L-arginine. A method for treating a disorder of a subject includes: administering to the subject a therapeutically effective amount of the composition for treating the disorder. The disorder is a vascular disorder, a complication of the vascular disorder, or a combination thereof.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 1, 2016
    Inventor: Shaker A. Mousa
  • Publication number: 20160257672
    Abstract: The present invention relates to pharmaceutical compositions comprising furan-2-sulfonamide derivatives. The present invention further relates to methods of treatment of diseases or conditions associated with endothelial lipase activity, including coronary artery disease and low HDL-C.
    Type: Application
    Filed: October 6, 2014
    Publication date: September 8, 2016
    Inventors: Magid Abou-Gharbia, Wayne E. Childers, Rogelio Martinez, Victor P. Ghidu, Harold Meyers, Shaker A. Mousa, Nabil Elshourbagy
  • Publication number: 20160256467
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil Elshourbagy, Harold Meyers, Shaker A. Mousa